8-K: Achieve Life Sciences Prices $45 Million Public Offering to Advance Cytisinicline Towards FDA Approval

Achieve Life Sciences, a late-stage specialty pharmaceutical company, has priced an underwritten public offering of common stock and accompanying warrants, aiming to raise approximately $41.3 million in net proceeds to fund the continued advancement of its lead product candidate, cytisinicline.

Summary

• Achieve Life Sciences, Inc. (Nasdaq: ACHV) has priced an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock.
• The securities were offered collectively at a public offering price of $3.00 per share and accompanying common warrant.
• The company has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock and/or accompanying common warrants.
• Each common warrant is exercisable for common stock at an exercise price of $3.00 per share or for pre-funded warrants at an exercise price of $2.999 per pre-funded warrant.
• Common warrants are exercisable any time after issuance, subject to certain ownership limitations, and expire five years from the date of issuance (June 30, 2030).
• Pre-funded warrants have a nominal exercise price of $0.001 per share, are immediately exercisable subject to ownership limitations, and have no expiration.
• The beneficial ownership limitation for both types of warrants is initially 9.99% of outstanding common stock, which can be increased or decreased to 19.99% with 61 days prior notice.
• Achieve estimates net proceeds from the offering to be approximately $41.3 million, after deducting underwriting discounts and commissions and estimated offering expenses, assuming no exercise of the over-allotment option.
• The company intends to use the proceeds to fund the continued advancement of cytisinicline through potential U.S. Food and Drug Administration (FDA) marketing approval and for working capital and general corporate purposes.
• The offering is expected to close on or about June 30, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there is dilution from the offering, the successful pricing and expected net proceeds of $41.3 million provide critical funding for the continued advancement of cytisinicline towards FDA approval, a significant milestone for a late-stage pharmaceutical company. This financing event de-risks the immediate funding needs for key strategic objectives.

Positives

• The offering is expected to raise approximately $41.3 million in net proceeds, providing crucial capital for the company's operations.
• Proceeds will be used to fund the continued advancement of cytisinicline through potential FDA marketing approval, indicating progress towards commercialization.
• Cytisinicline has already had its New Drug Application (NDA) submitted to the FDA for smoking cessation in June 2025, and has Breakthrough Therapy designation for vaping cessation, highlighting its potential market impact.
• The capital raise strengthens the company's financial position to pursue its strategic objectives in addressing nicotine dependence.

Negatives

• The issuance of 15,000,000 shares of common stock and 15,000,000 accompanying warrants, plus a potential over-allotment option, will result in significant dilution for existing shareholders.
• The offering price of $3.00 per share and warrant may be below recent trading prices, potentially indicating a discount to market value to attract investors.

Risks

• The actual results could differ materially from forward-looking statements regarding the expected closing date, net proceeds, and anticipated use of proceeds.
• Risks identified in Achieve's filings with the SEC, including its Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and the prospectus supplement related to the offering, could materially and adversely affect the company's results of operations and stock price.
• The company cautions against undue reliance on forward-looking statements, as actual outcomes may vary due to various uncertainties.

Future Outlook

Achieve Life Sciences intends to use the net proceeds from this offering to fund the continued advancement of cytisinicline through potential U.S. FDA marketing approval for smoking cessation and for working capital and general corporate purposes. The company has already submitted its New Drug Application (NDA) for cytisinicline for smoking cessation and has completed a Phase 2 study for vaping cessation, with Breakthrough Therapy designation from the FDA for a future vaping indication.

Management Comments

• Achieve intends to use the proceeds from the offering to fund continued advancement of cytisinicline through potential U.S. Food and Drug Administration marketing approval of cytisinicline and for working capital and general corporate purposes.

Industry Context

Achieve Life Sciences operates in the specialty pharmaceutical sector, specifically targeting nicotine dependence, a significant global health issue. The offering is a common strategy for late-stage pharmaceutical companies to secure capital for the expensive and lengthy process of clinical development, regulatory approval, and potential commercialization. The large addressable market for smoking (29 million U.S. adults) and e-cigarette cessation (17 million U.S. adults) underscores the potential demand for effective treatments like cytisinicline, especially given the lack of FDA-approved treatments specifically for e-cigarette cessation and cytisinicline's Breakthrough Therapy designation.

Comparison to Industry Standards

• The offering structure, combining common stock with warrants, is a common financing mechanism for biotechnology and pharmaceutical companies, particularly those in late-stage development, as it allows for immediate capital infusion while providing investors with potential upside through warrant exercise.
• The exercise price of $3.00 for common warrants and a nominal $0.001 for pre-funded warrants, alongside a public offering price of $3.00 per unit, aligns with typical structures designed to attract investors by offering a low-cost entry point for additional equity exposure.
• The 9.99% beneficial ownership limitation (with an option to increase to 19.99%) is a standard provision in such offerings to prevent immediate triggering of certain corporate governance or regulatory thresholds by large investors.
• The use of proceeds to fund clinical development and regulatory approval (specifically NDA submission for smoking cessation and plans for vaping indication) is consistent with the capital needs and strategic priorities of a late-stage pharmaceutical company.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience dilution due to the issuance of new shares and warrants, but the capital raise provides funding for product development, potentially increasing long-term value if cytisinicline achieves market success.
• Employees: The funding supports continued operations and product development, contributing to job security and the company's long-term viability.
• Customers (future): The capital enables the company to pursue FDA approval for cytisinicline, potentially bringing a new treatment option for nicotine dependence to market.
• Creditors: The capital raise improves the company's liquidity and financial stability, potentially reducing credit risk.

Next Steps

• The offering is expected to close on or about June 30, 2025, subject to customary closing conditions.
• Achieve Life Sciences will continue to advance cytisinicline through the potential U.S. FDA marketing approval process for smoking cessation.
• The company will continue to pursue a future vaping indication for cytisinicline, following a successful end-of-Phase 2 meeting with the FDA.

Key Dates

Keywords

Achieve Life Sciences, ACHV, Public Offering, Underwritten Offering, Common Stock, Warrants, Pre-Funded Warrants, Capital Raise, Cytisinicline, Nicotine Dependence, Smoking Cessation, Vaping Cessation, FDA Approval, Pharmaceutical, Biotechnology, SEC Filing, Form 8-K, Dilution